Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

V2 antagonist OPC-31260 prevents cerebral edema in rat model

Feb. 23, 1999

Dopamine D3 ligands in the BASF pipeline

Feb. 23, 1999

Novel heterocyclic CRF antagonists under study at DuPont

Feb. 23, 1999

Ceresine shows positive results in phase II trial in stroke patients

Feb. 22, 1999

Zeneca seeks European approval for Zomig formulation using OraSolv technology

Feb. 22, 1999

Dual 5-HT1A antagonists and 5-HT reuptake inhibitors emerge from research at Vita-Invest

Feb. 22, 1999

Peptidomimetic aspartyl protease inhibitors from Pharmacopeia for AD and malaria

Feb. 22, 1999

Biogen and Inhale enter agreement for pulmonary delivery of Avonex

Feb. 22, 1999

Dopamine D4-selective compounds, therapeutic and diagnostic uses disclosed by Resolution

Feb. 19, 1999

NO synthase inhibition reduces chronic tension headache pain

Feb. 19, 1999

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...